1. Home
  2. BTOG vs GNPX Comparison

BTOG vs GNPX Comparison

Compare BTOG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTOG

Bit Origin Limited

HOLD

Current Price

$4.24

Market Cap

6.6M

Sector

Finance

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.67

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTOG
GNPX
Founded
2018
2009
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
6.4M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
BTOG
GNPX
Price
$4.24
$2.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
102.9K
1.4M
Earning Date
03-31-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,495.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.39
$1.71
52 Week High
$60.60
$55.00

Technical Indicators

Market Signals
Indicator
BTOG
GNPX
Relative Strength Index (RSI) 77.40 52.68
Support Level $3.65 $2.10
Resistance Level $5.96 $3.11
Average True Range (ATR) 0.55 0.46
MACD 0.21 0.01
Stochastic Oscillator 69.89 39.38

Price Performance

Historical Comparison
BTOG
GNPX

About BTOG Bit Origin Limited

Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: